Pharmacogenomics of Interferon-Induced Depression

干扰素引起的抑郁症的药物基因组学

• 批准号: 7418658
• 负责人: FRANCIS E LOTRICH
• 金额: $ 17.36万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-06-01 至 2010-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7418658
• 关键词: Affect; Ancillary Study; Beck depression inventory; Biological Assay; Candidate Disease Gene; Class; Clinical Pharmacology; Computer software; Consultations; DNA; Data; Development; Drug Kinetics; Equipment and supply inventories; Exposure to; Future; Genes; Genetic; Genetic Polymorphism; Genetic Predisposition to Disease; Genome; Goals; Hepatitis C; Human; Human Genetics; Individual; Interferon-alpha; Interferons; Introns; Laboratories; Mental Depression; Mental Health; Micro Array Data; Modeling; Mus; Patients; Pharmacogenetics; Pharmacogenomics; Pilot Projects; Protocols documentation; Psychiatrist; Quantitative Genetics; Reading; Recording of previous events; Research; Research Design; Research Training; Role; Score; Techniques; Training; Treatment/Psychosocial Effects; Tryptophan 5-monooxygenase; cohort; depressive symptoms; design; genetic association; programs; promoter; prospective; psychosocial; response; serotonin transporter

DESCRIPTION (provided by applicant): The candidate for this K23 application is a psychiatrist who proposes to acquire expertise in pharmacogenomics. He intends to accomplish this goal through guided didactics and consultations and a research protocol designed to examine genetic polymorphisms that may affect vulnerability to interferon-alpha-induced depression (I-ID) in humans. Interferon-alpha can trigger depression in about 25% of patients and is the primary treatment for hepatitis C, which affects about 4 million individuals in the U.S. In addition to this being a significant mental health issue in its own right, I-ID offers the opportunity to feasibly examine a prospective human model of depression. Therefore, specific candidate polymorphisms will be examined in a well-characterized cohort of patients with hepatitis C who are assessed prior to interferon-a treatment and who are currently euthymic. The development of depression will be prospectively followed, along with pharmacokinetic assessments of interferon-a exposure. In conjunction with didactic training, this research will provide a platform for acquiring expertise in quantitative genetics and associational analyses in clinical pharmacology research, and designs using high throughput genetic polymorphism assays. The didactic training will involve specific classes in human genetics, supervised readings and software tutorials, and exposure to high throughput laboratory techniques. A small ancillary pilot study will also be included to ascertain, in parallel, potential candidate genes for further genetic association analyses of I-ID. This ancillary study will generate pilot micro-array data in an analogous murine model of interferon-alpha exposure, ascertaining the genome-wide set of frontal cortical genes affected by interferon-alpha. In conjunction with didactic training in the analysis and collaborative verification of micro-array data, this ancillary project will provide a training platform for incorporating the use of micro-arrays into psychiatric pharmacogenetic research. This developmental program will initiate the candidate's long-term interdisciplinary and integrative strategy for delineating genetic vulnerability to depression.

描述（由申请人提供）：本K23申请的候选人是一名精神科医生，他打算获得药物基因组学方面的专业知识。他打算通过指导教学和咨询以及旨在检查可能影响人类干扰素-α诱导抑郁症（I-ID）易感性的遗传多态性的研究方案来实现这一目标。干扰素-α可以引发约25%的患者抑郁症，并且是丙型肝炎的主要治疗方法，丙型肝炎影响了美国约400万人，除了这本身是一个重要的心理健康问题外，I-ID还提供了可行的机会来检查抑郁症的前瞻性人类模型。因此，将在一个充分表征的丙型肝炎患者队列中检查特定的候选多态性，这些患者在干扰素-a治疗前进行评估，目前胸腺功能正常。将前瞻性随访抑郁症的发展，沿着干扰素-a暴露的药代动力学评估。结合教学培训，本研究将提供一个平台，用于获得定量遗传学和临床药理学研究中的关联分析方面的专业知识，并使用高通量遗传多态性分析进行设计。教学培训将涉及人类遗传学的特定课程，监督阅读和软件教程，以及接触高通量实验室技术。一个小的辅助试点研究也将包括确定，在平行的，潜在的候选基因进一步的遗传关联分析I-ID。该辅助研究将产生试点微阵列数据在一个类似的小鼠模型的干扰素-α曝光，确定全基因组的额叶皮质基因受干扰素-α。结合微阵列数据分析和协作验证的教学培训，该辅助项目将提供一个培训平台，将微阵列的使用纳入精神病学药物遗传学研究。这个发展计划将启动候选人的长期跨学科和综合战略，以划定遗传易感性抑郁症。